This article is more than 5 years old. Information may no longer be current.

Allergan, Inspire to comarket allergy drug in United States

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — An ophthalmic anti-itching drug will be comarketed in the United States by Allergan and Inspire Pharmaceuticals, the companies announced in a joint press release.

Elestat (epinastine HCl ophthalmic solution) was approved for U.S. marketing for the prevention of itching associated with allergic conjunctivitis in October. Under terms of the agreement, in exchange for an up-front payment by Inspire to Allergan, Allergan will pay royalties on the drug’s net sales. Allergan will also reduce its royalty payment on Restasis (cyclosporine), according to the release.

Allergan expects to launch the allergy drug as Relestat in Europe in early 2004.